Skip to main content

Primary Membranous Nephropathy

Nephrology
4
Pipeline Programs
9
Companies
7
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
150%
Monoclonal Antibody
150%
+ 8 programs with unclassified modality

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Cerium Pharmaceuticals
Cerium PharmaceuticalsMD - Gaithersburg
1 program
1
SNP-ACTHPhase 31 trial
Active Trials
NCT05696613Unknown148Est. Mar 2026
Biocorp
BiocorpFrance - Issoire
2 programs
2
JMT601 InjectionPhase 21 trial
budoprutugPhase 2
Active Trials
NCT07029139Not Yet Recruiting156Est. Mar 2029
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
ALXN1920Phase 21 trial
Active Trials
NCT07157787Recruiting30Est. Jul 2027
Climb Bio
Climb BioMA - Wellesley Hills
1 program
budoprutugPHASE_21 trial
Active Trials
NCT07096843Recruiting45Est. Oct 2027
Vertex Pharmaceuticals
1 program
PovetaciceptPHASE_2_3
Labcorp
LabcorpBURLINGTON, NC
1 program
PovetaciceptPHASE_2_3
Zai Lab
Zai LabCA - South SF
1 program
PovetaciceptPHASE_2_31 trial
Active Trials
NCT07204275Recruiting176Est. Dec 2028
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
ZanubrutinibPHASE_2_3Small Molecule1 trial
Active Trials
NCT05707377Active Not Recruiting178Est. Oct 2027
Biogen
BiogenCAMBRIDGE, MA
1 program
FelzartamabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT06962800Recruiting180Est. Mar 2029

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
BiogenFelzartamab
Cerium PharmaceuticalsSNP-ACTH
Zai LabPovetacicept
BeOne MedicinesZanubrutinib
AstraZenecaALXN1920
Climb Biobudoprutug
BiocorpJMT601 Injection

Clinical Trials (7)

Total enrollment: 913 patients across 7 trials

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)

Start: May 2025Est. completion: Mar 2029180 patients
Phase 3Recruiting

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

Start: Mar 2023Est. completion: Mar 2026148 patients
Phase 3Unknown
NCT07204275Zai LabPovetacicept

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Start: Sep 2025Est. completion: Dec 2028176 patients
Phase 2/3Recruiting

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

Start: Apr 2023Est. completion: Oct 2027178 patients
Phase 2/3Active Not Recruiting

Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)

Start: Sep 2025Est. completion: Jul 202730 patients
Phase 2Recruiting

A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy

Start: Aug 2025Est. completion: Oct 202745 patients
Phase 2Recruiting
NCT07029139BiocorpJMT601 Injection

A Study to Learn More About the Effects and Safety of JMT601 in Adults With Primary Membranous Nephropathy

Start: Jun 2025Est. completion: Mar 2029156 patients
Phase 2Not Yet Recruiting

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
4 actively recruiting trials targeting 913 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.